Overview

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Status:
Completed
Trial end date:
2016-12-14
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection in open-label period
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
MedImmune Ltd